Brind.

Revolution Medicines develops targeted therapies for RAS-addicted cancers and uses LinkedIn for corporate communication.

4 reports, 4 independent Updated Sep 17
Gone quiet
Reports
4
Developments
1
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Revolution Medicines develops targeted therapies for RAS-addicted cancers and uses LinkedIn for corporate communication.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • fool.com
  • themarketsdaily.com
  • yahoo.comCan Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?
  • GlobeNewswireRevolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasda